What insights can the historical arrows in the Musée du quai Branly collection provide about Indigenous culture and design evolution? The collection, which includes 115 arrows from the Southeast and Central U.S. dating back to the 1700s, offers a unique glimpse into the craftsmanship and materials used by Indigenous peoples.
These arrows are primarily lightweight with thin shafts, a stark contrast to later Choctaw arrows that are known for their thicker and heavier construction. Made from materials such as river cane, hardwood, garfish scales, and deer antler, these arrows were likely intended for hunting small game, as indicated by their design.
Remarkably, some arrows in the collection bear teeth marks from the maker, who straightened them in his mouth over 300 years ago. This detail highlights the human aspect of these artifacts, as noted by experts who emphasize that “the arrows in this collection hold neat human details.”
Furthermore, the collection predates the Trail of Tears, providing a rare opportunity to study Indigenous culture before significant upheaval. The design evolution of Choctaw arrows over time can be traced through these artifacts, offering insights into changing materials and techniques.
Interestingly, only a few arrows in the collection feature metal tips, indicating a period when traditional materials were still predominant. This aspect of the collection underscores the transition in arrow-making techniques and materials used by Indigenous peoples.
In a different context, the term “arrow” also appears in the medical field, particularly in the ARROW study, which focuses on the treatment of RET fusion-positive non-small cell lung cancer (NSCLC). The final data from this study shows robust and durable responses to pralsetinib, a drug designed to selectively target RET in metastatic NSCLC.
Dr. Justin F. Gainor noted, “The final data from the ARROW study shows robust and durable responses with a manageable safety profile in patients with RET fusion-positive NSCLC.” This highlights the importance of early biomarker testing for patients with this specific type of cancer.
As the medical community continues to explore the implications of the ARROW study, the historical arrows in the Musée du quai Branly collection remind us of the rich cultural heritage that can be gleaned from artifacts. Both contexts emphasize the significance of understanding evolution—whether in design or medical treatment.
While the arrows provide a wealth of knowledge about Indigenous craftsmanship, the ongoing research in the medical field indicates that advancements in treatment options are also on the horizon. Details remain unconfirmed regarding the full impact of pralsetinib as a first-line treatment option, as noted by Dr. Lisa Rojkjaer, who stated, “These longer-term data further support pralsetinib’s role as a first-line treatment option for RET fusion-positive NSCLC patients.”